AP8

Last updated

AP8
AP8 structure.png
Identifiers
  • (2S,3R)-3-cyclopropyl-3-[(2R)-2-[1-[(1S)-1-[5-fluoro-2-(trifluoromethoxy)phenyl]ethyl]piperidin-4-yl]-3,4-dihydro-2H-chromen-7-yl]-2-methylpropanoic acid
PubChem CID
ChemSpider
Chemical and physical data
Formula C30H35F4NO4
Molar mass 549.607 g·mol−1
3D model (JSmol)
  • C[C@@H](C1=C(C=CC(=C1)F)OC(F)(F)F)N2CCC(CC2)[C@H]3CCC4=C(O3)C=C(C=C4)[C@H](C5CC5)[C@H](C)C(=O)O
  • InChI=1S/C30H35F4NO4/c1-17(29(36)37)28(21-4-5-21)22-6-3-19-7-9-25(38-27(19)15-22)20-11-13-35(14-12-20)18(2)24-16-23(31)8-10-26(24)39-30(32,33)34/h3,6,8,10,15-18,20-21,25,28H,4-5,7,9,11-14H2,1-2H3,(H,36,37)/t17-,18-,25+,28-/m0/s1
  • Key:ADYYYLTWZYYGNX-LJYIQKJHSA-N

AP8 is an experimental drug which acts as a selective agonist for the free fatty acid receptor FFAR1 (GPR40). It has antiinflammatory and anti-fibrotic effects. [1] [2] [3]

References

  1. Lu J, Byrne N, Wang J, Bricogne G, Brown FK, Chobanian HR, et al. (July 2017). "Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40". Nature Structural & Molecular Biology. 24 (7): 570–577. doi:10.1038/nsmb.3417. PMID   28581512.
  2. Atanasio S, Deganutti G, Reynolds CA (November 2020). "Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics". Journal of Computer-aided Molecular Design. 34 (11): 1181–1193. Bibcode:2020JCAMD..34.1181A. doi:10.1007/s10822-020-00338-6. PMID   32851580.
  3. An X, Bai Q, Bing Z, Liu H, Yao X (2021). "Insights into the molecular mechanism of positive cooperativity between partial agonist MK-8666 and full allosteric agonist AP8 of hGPR40 by Gaussian accelerated molecular dynamics (GaMD) simulations". Computational and Structural Biotechnology Journal. 19: 3978–3989. doi:10.1016/j.csbj.2021.07.008. PMC   8313488 . PMID   34377364.